Low incidence of rimantadine resistance in field isolates of influenza A viruses

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 935-939

  Ziegler, Thedi ^a,c,d   Hemphill, Mark L ^a   Ziegler, Marja Liisa ^a,c,d   Perez Oronoz, Gilda ^a   Klimov, Alexander I ^a   Hampson, Alan W ^b   Regnery, Helen L ^a   Cox, Nancy J ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CSL LIMITED   (Australia)

^c UNIVERSITY OF OULU   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; RIMANTADINE;

ARTICLE; DRUG SENSITIVITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; CELL LINE; DOGS; DRUG RESISTANCE, MICROBIAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; RIMANTADINE; VIRAL MATRIX PROTEINS; WORLD HEALTH;

EID: 0033370575     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314994     Document Type: Article

References (29)

1. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infections. N Engl J Med 1982;307:580-4.
2. Sears SD, Clements ML. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother 1987;31:1470-3.
3. Crawford SA, Clover RD, Abell TD, Ramsey CN, Glezen WP, Couth RB. Rimantadine prophylaxis in children: a follow-up study. Pediatr Infect Dis J 1988;7:379-83.
4. Brady MT, Sears SD, Pacini DL, et al. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob Agents Chemother 1990;34:1633-6.
5. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987;80:275-82.
6. Tominack RL, Hayden, FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am 1987;1:459-78.
7. Douglas G Jr. Prophylaxis and treatment of influenza. N Engl J Med 1990;322:443-50.
8. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-702.
9. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991;35:1741-7.
10. Degelau J, Somani SK, Cooper SL, Guay DRP, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992;152:390-2.
11. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Arch Intern Med 1995;155:533-7.
12. Hayden FG. Amantadine and rimantadine clinical aspects. In: Richman DG, ed. Antiviral Drug Resistance. Chichester: John Wiley, 1996;59-77.
13. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromized adults. Clin Infect Dis 1998;26:1418-24.
14. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992;3:21-30.
15. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992;69:517-28.
16. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993;67:5585-94.
17. Holsinger IJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994;68:1551-63.
18. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988;62:1508-12.
19. Zlydnikov DM, Kubar OI, Kovaleva TP, Kamforin LE. Study of rimantadine in the USSR: a review of the literature. Rev Infect Dis 1981;3:408-21.
20. Valette M, Allard JP, Aymard M, Millet V. Susceptibilities to rimantadine of influenza A/H1N1 and A/H3N2 viruses isolated during the epidemics of 1988 to 1989 and 1989 to 1990. Antimicrob Agents Chemother 1993;37:2239-40.
21. Kendal AP. Reference viruses for use in amantadine sensitivity testing of human influenza A viruses. Antivir Chem Chemother 1991;2:115-8.
22. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF. Cox NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995;172:1352-5.
23. Belshe RB, Buck B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989;159:430-5.
24. Cox NJ, Brammer TL, Regnery HL. Influenza: global surveillance for epidemic and pandemic variants. Eur J Epidemiol 1994;10:467-70.
25. Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 1989;159:1050-6.
26. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45(RR-5):1-24.
27. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis 1992;15:362-7.
28. Von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23.
29. Blick TJ, Tiong T, Sahasrabudhe A, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995;214:475-84.